Based on the current market data and recent analyst ratings, ALNY stock appears to be in a consolidation phase with a slight bearish bias at $272.69, down 1.27% in regular trading hours. The stock shows mixed technical signals with an RSI of 60.15 indicating neutral momentum, while trading above its 20-day SMA of $266.19. Recent analyst coverage remains strongly bullish with multiple "Buy" and "Strong Buy" ratings and price targets ranging from $300 to $400, suggesting significant upside potential from current levels. The company's anticipated non-GAAP profitability achievement in 2025 and strong revenue guidance of $2.050-2.250 billion for 2025 provide fundamental support for the stock.

What is price prediction 2025 for ALNY Stock?

Based on recent data and market analysis, ALNY stock is projected to reach $310-315 by end of 2025, driven by the company's anticipated achievement of non-GAAP profitability in 2025 and strong revenue growth guidance of $2.05-2.25 billion representing 31% year-over-year growth at midpoint. The company's positive Phase 1 data for nucresiran and FDA orphan designation for ATTR amyloidosis treatment further strengthen this bullish outlook. Technical indicators show RSI at 60.15 with positive MACD of 7.61, suggesting continued upward momentum from current price levels.

What is surpport and resistant level for ALNY Stock?

The S1 support level for ALNY Stock is $268.36 ,The R1 resistant level for ALNY Stock is $281.61.

What is the current price of ALNY Stock?

As of the end of day on 2025-02-11, the price of ALNY Stock was $269.34.

What is the target price of ALNY Stock?

The target price for ALNY Stock according to analyst rating is 312.80, with the highest price target at 400.00 and the lowest at 205.00. Analysts have a Moderate Buy rating on ALNY Stock overall.

What is the market cap of Alnylam Pharmaceuticals Inc?

The market cap of ALNY is $35.3B.

Is Alnylam Pharmaceuticals Inc (ALNY) overvalued?

Based on the provided data and current market context, here's an analysis of ALNY's valuation:

Valuation Analysis ALNY shows concerning valuation metrics with a high P/S ratio of 16.64 in Q3 2024, indicating the stock is trading at a premium relative to its sales. The company's negative earnings make traditional P/E metrics less meaningful for valuation assessment.

Financial Performance The company's Q3 2024 financials reveal a net loss of $111.57 million with declining net margins (-22.27%), suggesting operational challenges. However, revenue growth remains strong with Q3 2024 revenue at $500.92 million.

Growth Prospects According to recent guidance, Alnylam expects 2025 combined net product revenue of $2.05-2.25 billion, representing 31% year-over-year growth at the midpoint. The company also anticipates achieving non-GAAP profitability in 2025, marking a significant milestone.

Analyst Sentiment Recent analyst coverage shows mixed but generally positive sentiment. RBC Capital maintained a Buy rating with a $300 price target on January 21, 2025, while Needham reiterated a Strong Buy with a $320 target on January 13, 2025. HC Wainwright remains the most bullish with a $400 target.

Conclusion Given the high valuation multiples, current losses, but strong revenue growth prospects and anticipated profitability in 2025, ALNY appears overvalued at current levels. The stock's premium valuation requires perfect execution on growth targets and profitability goals to justify current prices.

What is Alnylam Pharmaceuticals Inc (ALNY)'s business?

Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.

What is price prediction 2030 for ALNY Stock?

Based on the available data and market analysis, here is the price prediction for ALNY stock by 2030:

ALNY stock is projected to reach $450-500 by 2030, driven by the company's strong RNAi therapeutics pipeline and expected non-GAAP profitability achievement in 2025. The company's preliminary 2025 revenue guidance of $2.05-2.25 billion represents 31% year-over-year growth, demonstrating robust commercial execution. Recent FDA orphan designation for their ATTR amyloidosis treatment further strengthens their market position.

The stock's technical indicators show an RSI of 60.15 and positive MACD of 7.61, suggesting moderate upward momentum while trading above its 200-day moving average of $237.71, supporting the long-term bullish outlook.